Bisoprolol, a β1 antagonist, protects myocardial cells from ischemia–reperfusion injury via PI3K/AKT/GSK3β pathway
Male
Cardiotonic Agents
Glycogen Synthase Kinase 3 beta
Myocardial Reperfusion Injury
Adrenergic beta-1 Receptor Antagonists
Rats
3. Good health
Rats, Sprague-Dawley
Disease Models, Animal
Phosphatidylinositol 3-Kinases
03 medical and health sciences
0302 clinical medicine
Animals
Bisoprolol
Myocytes, Cardiac
Proto-Oncogene Proteins c-akt
Signal Transduction
DOI:
10.1111/fcp.12562
Publication Date:
2020-05-04T05:42:53Z
AUTHORS (6)
ABSTRACT
AbstractThe aim of this work was to explore whether bisoprolol plays a protective role in cardiomyocytes against ischemia–reperfusion injury via PI3K/AKT/ GSK3β pathway. We pretreated male Sprague Dawley (SD) rats with bisoprolol by oral administration prior to 0.5 h ischemia/4 h reperfusion. Myocardial infarct size and serum levels of cTnI and CK‐MB were measured. In vitro, H9c2 cells were treated with hypoxia and reoxygenation, followed by measurement of cell viability, apoptosis, ROS production, cytometry, activities of AKT, GSK3β, and p‐38 in the presence and absence of GSK3β siRNA. We found that bisoprolol reduced infarct size from 44% in I/R group to 31% in treated group (P < 0.05). The levels of cTnI and CK‐MB were decreased from 286 ± 7 pg/mL and 32.2 ± 2 ng/mL in I/R group to 196 ± 2 pg/mL and 19.6 ± 0.9 ng/mL in the treated group, respectively (P < 0.05). Bisoprolol also increased cell viability while decreased apoptosis and ROS production in the treatment of hypoxia/ reoxygenation. Furthermore, bisoprolol increased AKT and GSK3β phosphorylation, an effect that was immediately eliminated by LY294002. GSK3β‐specific siRNA experiment further confirmed that bisoprolol protected the myocardium against hypoxia/reoxygenation‐induced injury via suppressing GSK3β activity. In conclusion, bisoprolol protected myocardium against ischemia–reperfusion injury via the PI3K/AKT/ GSK3β pathway.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (47)
CITATIONS (9)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....